Virax Biolabs Group Limited Ordinary Shares - Asset Resilience Ratio
Virax Biolabs Group Limited Ordinary Shares (VRAX) has an Asset Resilience Ratio of 1.47% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read VRAX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Virax Biolabs Group Limited Ordinary Shares's Asset Resilience Ratio has changed over time. See shareholders equity of Virax Biolabs Group Limited Ordinary Sha for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Virax Biolabs Group Limited Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VRAX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $94.19K | 1.47% |
| Total Liquid Assets | $94.19K | 1.47% |
Asset Resilience Insights
- Limited Liquidity: Virax Biolabs Group Limited Ordinary Shares maintains only 1.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Virax Biolabs Group Limited Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Virax Biolabs Group Limited Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Virax Biolabs Group Limited Ordinary Shares (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Virax Biolabs Group Limited Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.47% | $94.19K | $6.43 Million | +0.06pp |
| 2024-03-31 | 1.41% | $77.32K | $5.48 Million | +0.91pp |
| 2023-03-31 | 0.50% | $49.26K | $9.81 Million | -- |
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more